Further to its earlier communication dated 5TH August 2026 regarding the inspection by the United States Food and Drug Administration (USFDA) at the Company's manufacturing facility located at Pashamylaram, Hyderabad (FEI No. 1000623515), Cohance Lifesciences has informed that, USFDA has issued the Establishment Inspection Report (EIR) in respect of the aforesaid facility and has classified the inspection outcome as Voluntary Action Indicated (VAI). With the receipt of the EIR, the said inspection stands concluded.
The above information is a part of company’s filings submitted to BSE.